Renal artery embolization in the treatment of urinary fistula after renal duplication:A case report and review of literature

BACKGROUND Duplicate renal malformation is a congenital disease of the urinary system,with an incidence rate of 0.8%.Surgical treatment is suitable for symptomatic patients.Urinary fistula is one of the complications of heminephrectomy.Long-term urinary fistula has a great impact on patients'lives.CASE SUMMARY This article mainly reports on a 47-year-old man with duplication of kidney deformity,long urinary fistula after partial nephrectomy,and no improvement after conservative treatment.We have achieved positive results in the arterial embolization treatment of the residual renal artery,indicating that selective arterial embolization is a good way to treat urinary fistula after partial nephrectomy.It is worth noting that this patient violated the Weigert-Meyer law,which also gave us more consideration.CONCLUSION Renal artery embolization may be a simple and safe method to treat urinary fistula inefficacy with conservative treatment.

Efficacy of nonsolvent flower pollen extracts in healthy women with urinary incontinence:A randomized,double-blind,placebo-controlled,parallel study

Background Urinary incontinence(UI)is a debilitating and common condition that adversely affects quality of life.Prescriptive and surgical approaches for managing UI symptoms may result in undesirable risks and complications.This randomized,double-blind,placebo-controlled,parallel study investigated the efficacy of 2 nonsolvent flower pollen extracts on UI in healthy women.Materials and methods One-hundred and fourteen women aged 40–75 years who scored≥5 on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form(ICIQ-SF)were randomized to receive either Graminex®RCT Fem™UI,Graminex®PollenBerry®,or placebo for 24 weeks.The primary outcome was the change in the ICIQ-SF score between the trial and placebo groups after 24 weeks of supplementation.The secondary outcomes included changes in the frequency of nocturia(recorded in 3-day void diaries)and 24-hour leakage volume(assessed via pad weight)after 6,12,18,and 24 weeks of supplementation and changes in stress-induced urinary leakage volume(after completion of a provocative maneuver challenge)after 24 weeks of supplementation.Results All the groups demonstrated improvement in ICIQ-SF scores at week 24(p<0.001).The RCT Fem™UI group had the greatest improvement in ICIQ-SF scores(−4.07±3.4),followed by the PollenBerry®group(−3.34±2.87)and placebo group(−2.61±3.52).The RCT Fem™UI group had corresponding improvements in 24-hour leakage volume(−17.68±39.84 g)and frequency of nocturia(−0.52±1.26)(p≤0.05).PollenBerry®supplementation significantly improved stress-induced urinary leakage volume(−7.12±15.64 g)at week 24.The study products demonstrated safe hematological and chemical profiles.Conclusions RCT Fem™UI supplementation resulted in significant and clinically meaningful reductions in UI severity,with corresponding improvements in daily urinary leakage volume and frequency of nocturia.PollenBerry®significantly improved stress-induced urinary leakage volume,suggesting that it may be efficacious in women who are prone to stress UI.The study products were safe and well tolerated in this population.